JP Morgan initiated coverage on Health Management Associates (NYSE: HMA) with a Neutral rating and a $9 price target.
JP Morgan commented, “Although reform should provide a solid boost, HMA offers relatively less upside potential from reform-based coverage expansion when compared to its peers according to our JPM Healthcare Reform Model. When this more modest EBITDA upside versus peers (~8% vs. ~10% group average) is coupled with company specific headline risks related to government investigations into admission practices and the potential for this to negatively impact future volumes as well as M&A prospects, we see HMA as a comparatively less attractive name in the group.”
Health Management Associates closed at $8.28 on Monday.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Tags: JP Morgan
Posted in: Analyst Color, Price Target, Pre-Market Outlook, Analyst Ratings